Patents Examined by Timothy R Rozof
  • Patent number: 10981936
    Abstract: Oligomeric compounds useful as organic conjugated materials in electronic devices. Oligomeric compounds contain three or more or four or more of certain PDI units bonded to an organic core. The organic core contains one, two or more thiophene rings. The organic core can contain two or more thiophene rings separated by a linker group; two or more thiophene rings directly fused to each other or indirectly fused to each other through an optionally substituted aromatic or non-aromatic carbocylic ring system or an optionally substituted aromatic heterocyclic or non-aromatic heterocyclic ring system; or each of two or more thiophene rings is fused to an aromatic or non-aromatic carbocylic ring system or an aromatic heterocyclic or non-aromatic heterocyclic ring system and the resulting fused rings containing a thiophene ring are each separated by a linker group M. Methods for making oligomeric compounds by direct heteroarylation are provided.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: April 20, 2021
    Assignee: UTI Limited Partnership
    Inventors: Abby-Jo Payne, Gregory C. Welch
  • Patent number: 10978255
    Abstract: A bichromic bipodal triphenyl amine based dye of the following formula: n 0 1 0 2 2 2 0 1 3 3 3 3 0 1?2 m 0 0 1 0 1 2 2 2 0 1 2 3 3 3?3 Wherein R=
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: April 13, 2021
    Inventors: Bryan Koivisto, Benjamin J. D. Fischer, Omar K. Abdi, Olga Sarycheva, Burhan A. Hussein, Selvyn Simoes, Francis Buguis, Hardeep S. Devgan
  • Patent number: 10975056
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 13, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.
    Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
  • Patent number: 10975052
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: April 13, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10961210
    Abstract: The present disclosure provides a process for producing an aliphatic sulfonyl azide anhydride and the resultant aliphatic sulfonyl azide anhydride composition. The process includes: (i) thio-acetoxylating an alkenyl carboxylic acid anhydride to form a thioacetate anhydride intermediate, (ii) oxy chlorinating the thioacetate anhydride intermediate to form a sulfonyl chlorideanhydride intermediate; and (iii) azidizing the sulfonyl chloride anhydride intermediate to form an aliphatic sulfonyl azide anhydride.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: March 30, 2021
    Assignee: Dow Global Technologies LLC
    Inventors: Adriana I. Moncada, Brian W. Walther, Jerzy Klosin, Ahmad E. Madkour
  • Patent number: 10961211
    Abstract: Isotopically-stabilized tetronimide compounds comprising one or more deuterium atoms, derivatives, and intermediates, thereof, including methods for their synthesis, pharmaceutical compositions thereof, and methods of using these compounds to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are disclosed. One aspect relates to molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) ?-hydroxylase (ASPH) within or on the surface of a cell. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases. Related aspects include uses of the compounds to modulate the activity of viruses, as anti-hyperlipidemia agents, and as agents to ameliorate or treat thrombosis and related cardiovascular and metabolic disorders.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: March 30, 2021
    Assignee: Midwestern University
    Inventors: Mark Jon Olsen, Jean Paul Seerden
  • Patent number: 10961260
    Abstract: The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 30, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Seonkyoung Son, Cheol Jun Song, Milim Lee, Hoyong Lee
  • Patent number: 10959974
    Abstract: Provided in the present invention are ingenol compounds and a use thereof in preparing an anti-HIV latency drug. In particular, provided in the present invention is a use of ingenol compounds and pharmaceutically acceptable salts thereof for preparing a drug for: (a) intervening with HIV viral latency; (b) activating an HIV virus that has been integrated into mammalian genomes; and/or (c) inducing the expression of the dormant HIV provirus in infected cells. The compounds of the present invention may also be used in combination with antiretroviral drugs to accelerate the removal of latent viral reservoirs.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 30, 2021
    Inventors: Longfei Zhang, Pengfei Wang, Zhongjun Ma, Huanzhang Zhu
  • Patent number: 10961200
    Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 30, 2021
    Inventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
  • Patent number: 10954391
    Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, L6, M1, M2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: March 23, 2021
    Assignee: Sony Corporation
    Inventors: Tracy Matray, Hesham Sherif, C. Frederick Battrell
  • Patent number: 10954209
    Abstract: A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in Cannabis oil reacts with acetic anhydride with hexane and under reflux to produce THC-O-acetate and acetic acid using sulfuric acid as a catalyst. The resulting crude product is distilled and subjected to a SALLE with hexane followed by a SALLE with petroleum ether, before being distilled again in order to obtain a refined, THC-O-acetate product.
    Type: Grant
    Filed: September 15, 2019
    Date of Patent: March 23, 2021
    Assignee: Nextleaf Solutions Ltd.
    Inventor: David Novitski
  • Patent number: 10945947
    Abstract: The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: March 16, 2021
    Inventors: Rachel Apfelbaum, Andrew James Peat, Yoon Oh
  • Patent number: 10947208
    Abstract: A method for preparing sugar-based mono and diesters is described. The process entails the esterification of 2,5-furan-dicarboxylic acid (FDCA) with an alcohol in the presence of low loadings of a homogeneous organotin (IV) catalyst.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: March 16, 2021
    Inventors: Kenneth Stensrud, Stuart Fergusson
  • Patent number: 10947253
    Abstract: Novel fused tricyclic or bicyclic dimers, such as ?-carboline and quinoline moieties with a central linker, exhibit anti-cancer activities against a variety of human cancer cell lines. The dimer compounds can be used in anti-cancer therapeutic compositions useful in the treatment of human cancers.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 16, 2021
    Assignee: Ankh Life Sciences Limited
    Inventors: Brian Scott Johnathan Blagg, Vishal Chandrakumar Birar, Gene H. Zaid
  • Patent number: 10941155
    Abstract: The present invention discloses a novel furo[2,3-b]pyran-2-one compound of formula (I) and a single step process for the preparation of furo[2,3-b]pyran-2-ones using Lewis acid-promoted cascade annulation of alkynols and ?-ketoesters.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 9, 2021
    Assignee: Council of Scientific & Industrial Research
    Inventors: Ravindar Kontham, Sagar Sudam Thorat
  • Patent number: 10941141
    Abstract: Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: March 9, 2021
    Inventors: Xin-Yun Huang, Christy Young Shue
  • Patent number: 10941138
    Abstract: The present invention relates to new compounds of formula (I): showing great affinity and activity towards the subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels or dual activity towards subunit ?2? of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels, and the noradrenaline transporter (NET).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 9, 2021
    Inventors: Carmen Almansa-Rosales, Susana Yenes-Mínguez, Marina Virgili-Bernado, Monica Alonso-Xalma
  • Patent number: 10927105
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 23, 2021
    Inventors: Cheryl A. Grice, John J. M. Wiener, Olivia D. Weber, Katharine K. Duncan
  • Patent number: 10927107
    Abstract: The present invention relates to phenyl [a]indole[2,3-g]quinolizine compounds represented by formula (I), a preparation method therefor, a pharmaceutical composition, and applications thereof. Specific applications are applications in the preparation of drugs for treating diseases related to a proprotein convertase subtilisin Kexin-9 (PCSK9), comprising the applications in the preparation of drugs for treating hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver deformation, atherosclerosis, obesity and other metabolic diseases.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: February 23, 2021
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Yiping Wang, Fei Zhao, Jing Zhao, Jiang Wang, Cong Xi, Chenglin Wu, Hao Shen, Xu Han, Hualiang Jiang, Kaixian Chen
  • Patent number: 10927135
    Abstract: Provided herein are phosphates, thiophosphates, phosphonates, and phosphinates, methods of making same, and methods of using these compounds and methods for the generation of pharmaceutically relevant phosphate, phosphonate, and phosphinate analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: February 23, 2021
    Inventors: Jun Yong Kang, Hai Huang